Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Academic Article uri icon

Overview

abstract

  • Cultured endothelial cells derived from human umbilical veins or bovine aorta produce a potent inhibitor of platelet aggregation. The inhibitor is synthesized from sodium arachidonate or or prostaglandin endoperoxides by a microsomal enzyme system. Tranylcypromine, a specific antagonist of prostacyclin synthetase, suppresses production of the inhibitor by endothelial cells. The inhibitor, which is ether extractable, has been identified using a two-step thin-layer radiochromatographic procedure and a synthetic prostaglandin I2 standard. With this procedure, we have shown that human and bovine endothelial cells convert sodium [3H]arachidonate to radiolabeled prostaglandin I2 and 6-keto-prostaglandin F1alpha, as wellas prostaglandin E2. Thus, endothelial cells may be non-thrombogenic in vivo because they synthesize and release prostaglandin I2, a potent inhibitor of platelet aggregation.

publication date

  • September 1, 1977

Research

keywords

  • Aorta
  • Epoprostenol
  • Prostaglandins
  • Umbilical Veins

Identity

PubMed Central ID

  • PMC431786

Scopus Document Identifier

  • 0017527971

Digital Object Identifier (DOI)

  • 10.1073/pnas.74.9.3922

PubMed ID

  • 333448

Additional Document Info

volume

  • 74

issue

  • 9